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Abstract
Background: Prostate cancer (PCa) is the most commonly diagnosed malignancy reported to Australian
cancer registries with numerous studies from individual registries summarizing diagnostic and treatment
characteristics. The aim of this study was to describe annual trends in clinical and treatment characteristics,
and changes in surveillance practice within a large combined cohort of men with PCa in South Australia (SA)
and Victoria, Australia in 2008–2013.
Methods: Common data items from clinical registries in SA and Victoria were merged to develop a cross-
jurisdictional dataset consisting of 13,598 men with PCa. Frequencies were used to describe these variables
using the National Comprehensive Cancer Network risk of disease progression categories in 10 year age
groups. A logistic regression analysis was performed to assess the impact of a number of factors (both
individually and together) on the likelihood of men receiving no active treatment within twelve months of
the diagnosis (i.e. managed with active surveillance/watchful waiting).
Results: Trend analysis showed that over time: (1) men in SA and Victoria are being diagnosed at older age in 2013,
66.1 (SD = 9.7) years compared to 2009 (64.5 (SD = 9.7)); (2) diagnostic methods and characteristics have changed with
time; and (3) types of the treatments have changed, with more men having no active treatment. The majority of men
were diagnosed with Prostate-Specific Antigen (PSA) <10 ng/mL (66 %) and Grade Group < 4 (65 %). Nearly seventy
percent received radical treatment within 12 months of diagnosis, while ~20 % had no active treatment. In 14 % of
cases treatment was not recorded or had not commenced. Having no active treatment was strongly associated older
age, lower PSA and lower Grade Group at diagnosis, and in 2013 it was offered more frequently (more than 3 times)
than in 2009 (OR = 2.63, 95 % CI: 2.16–3.22).
Conclusions: Findings of this study provide the first cross-jurisdictional description of PCa characteristics and
management in Australia. These findings will provide benchmarking for ongoing monitoring and feedback of disease
management and outcomes of PCa through the Prostate Cancer Outcomes Registry–Australia New Zealand to
improve evidence-based practice.
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Background
Prostate cancer (PCa) is the most common and preva-
lent tumour reported to registries in Australia and
overseas [1, 2]. Management of PCa is complex and de-
pends on patient factors such as disease characteristics
at diagnosis, personal preferences, existing comorbidities,
and sometimes distance to treatment centres. Treatment
options include radical prostatectomy, radiotherapy,
brachytherapy, and hormone deprivation therapy, depend-
ing largely on grade and stage of disease at diagnosis.
Chemotherapy may be provided for palliative treatment
and survival benefit for late stage PCa.
Numerous hospital-based registries in Australia and
overseas have been collecting information relating on
men with PCa, including disease staging, risk factors, co-
morbidities, treatment modalities and patient reported
quality of life (QOL) at various points after diagnosis or
treatment [2–6]. Such registries aim not only to assess
and monitor patterns and quality of care for men diag-
nosed with PCa, but also to eventually improve their
long term outcomes.
Data extracted from both clinical and population-
based registries have been utilized in numerous studies
describing annual trends in the diagnosis, clinical char-
acteristics, and factors associated with various treatment
modalities, and survival trends in Australia and other
countries. Feletto et al. [7] in their recent study com-
pared the incidence and mortality rates of PCa in
Australia, USA, Canada and England, and demonstrated
that incidence rates in these countries are likely to be
heavily influenced by prostate-specific antigen (PSA)
testing, and that there was a fall in mortality that oc-
curred too soon to be solely a result of testing. Cooper-
berg et al. [3] in their study described trends in primary
management of low risk disease and concluded that a
significant and growing number of men with low risk
disease are possibly over-treated. Meng et al. [8] exam-
ined predictors of treatment modalities in patients after
initial surveillance. Of the 457 men initially offered no
active treatment, 188 (41 %) went on to active treatment
at a median of 1.7 years after diagnosis. Baseline charac-
teristics associated with progression to active treatment
included younger age, higher level of formal education,
higher PSA at presentation of the disease and higher
Gleason score.
Several studies describing trends in the diagnosis of
PCa, prevalence and patterns of care were also con-
ducted in Australia [9–12]. These studies have generally
been limited to individual hospitals or registries and
have not examined patterns across multiple jurisdictions.
The only cross-jurisdictional study undertaken in
Australia had limitations as it was based on data from
centralised cancer registries which do not collect detail
on clinical characteristics or treatments [13].
Studies across multiple registries generally provide
broader coverage and strengthen the evidence base for
evaluating patterns of care and patient outcomes; and
point to opportunities for improving health outcomes in
Australia [14–16]. Results from multiple registries are
more generalizable than those from single registries as
they would be well placed to find and control for add-
itional sources of variation and take advantage of natural
policy experiments.
To date, much of the evidence that guides clinical
management decisions in men with PCa in Australia has
been derived from international studies. It is unclear
whether clinical characteristics and treatment patterns
and outcomes among Australian men are comparable to
those of men in the USA or Europe, where much of the
international research is based. Therefore, the main ob-
jective of the present study was to provide an overview
of socio-demographic and clinical characteristics of pa-
tients with PCa, their treatment patterns and outcomes
using the data combined from two clinical registries in
the states of South Australia (SA) and Victoria. The
secondary objective of the study was to examine and
describe potential factors associated with receiving no
active treatment of the disease.
Methods
Study population
Beginning in 2013, the Movember Foundation, a glo-
bal Men’s Health Charity Organisation founded and
based in Australia, funded an initiative to seek con-
sensus for implementation of a bi-national population
based prostate cancer registry – the “Prostate Cancer
Outcomes Registry –Australia New and Zealand”
(PCOR-ANZ) [17]. Subsequently, a research collabor-
ation has been partnered between the University of
South Australia, Monash University, Movember and
the South Australian Health and Medical Research
Institute to establish the Movember Prostate Cancer
Health Outcomes Research Unit, aiming to improve
outcomes of men with PCa. To address this unit’s
goals, which also include objectives of this study, we
developed a dataset, containing amalgamated records
of men with PCa from the South Australian (SA) and
the Victorian PCa registries [18].
The Victorian Prostate Cancer Registry (now termed
the Prostate Cancer Outcomes Registry-Victoria, or
PCOR-Vic), based at Monash University, was established
in 2008 [19]. The registry collects data on PCa cases
from 38 metropolitan and regional public and private
hospitals in Victoria. The South Australian Prostate
Cancer Clinical Outcomes Collaborative (SA-PCCOC)
database, based in SA, was established in 1998 to include
men with PCa at all major teaching and treatment hos-
pitals in SA [5]. More recently the database has been
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expanded to include private treatment facilities. Cur-
rently the registry contains data on more than 11,000
patients.
A total of 13,598 records of PCa men diagnosed and
consented between 2008 and 2013 in SA and Victoria
were merged into the SA-Victorian PCa health outcomes
research dataset [18]. This combined dataset was devel-
oped, as a forerunner to the PCOR-ANZ [17], which is
currently underway, and one of the primary objectives
was to demonstrate the feasibility and value of collating
and amalgamating clinical data on prostate cancer treat-
ment and outcomes across jurisdictions, by combining
data from the two states in which multi-institutional
clinical registries already existed.
This combined dataset contains data on patient demo-
graphics characteristics, initial diagnosis and disease sta-
ging information, PSA history, clinical examination
results, treatment details, comorbidities and complica-
tions. Follow-up data are derived from the monitoring of
PSA values, clinical evidence of recurrence, any further
biopsy and pathology reported, as well as patient re-
ported symptoms and QOL data.
Records of men diagnosed with histologically con-
firmed PCa between 2008 and 2013 were included into
this study. Detailed information about the steps of data
collection and SA and Victoria clinical registries is pro-
vided elsewhere [2, 9].
Explanatory variables
Variables extracted for analysis included the year of diag-
nosis, patient’s age (10-year age groups) and socioeco-
nomic status derived from residential postcodes using
the Australian Bureau of Statistic’s Socioeconomic In-
dexes for Areas (SEIFA) [20]. PSA levels were grouped
into four categories: (1) <4 ng/mL, (2) 4.01–10 ng/mL,
(3) 10.01–20 ng/mL, and (5) >20 ng/mL. Five Grade
Groups were used: (1) Grade Group 1, where Gleason
score < =6, (2) Grade Group 2, where Gleason score = 3
+ 4, (3) Grade Group 3, where Gleason score = 4 + 3, (4)
Grade Group 4, where Gleason score = 8, and (5) Grade
Group 5, where Gleason score > =8 [21, 22].
The National Comprehensive Cancer Network (NCCN)
risk criteria for disease progression were used to classify
patients into low-, intermediate- high-risk and very high
risk (v.high)/metastatic disease (Table 1) [23]. Where
the clinical T category was not recorded, if the Grade
Group was 1 and the PSA concentration was <10 ng/
mL, the patient was deemed to be at low risk for dis-
ease progression [10].
Initial treatments within twelve months of the diagno-
sis were included in the analysis and classified into: (1)
radical prostatectomy (RP), (2) radiotherapy (RT), (3)
Androgen Deprivation Therapy (ADT), (4) active sur-
veillance/watchful waiting (no active treatment), and (5)
others (high intensity focused ultrasound, cryotherapy,
chemotherapy etc.). Note that we could not reliably dif-
ferentiate watchful waiting from active surveillance
across the two states, and thus we have called them “no
active treatment”. Where treatment information was
missing (i.e. the treatment field in the registry was left
blank) it was coded as ‘unknown’ rather than no active
treatment. Active treatment was defined as any RP, RT,
ADT or other treatment, but excluded no active treat-
ment option. Time to the first active treatment within
twelve months was calculated as a difference in days be-
tween the date of diagnosis and commencement of the
first treatment. Further information about treatment
types and groups is available elsewhere [18].
Statistical analysis
Descriptive statistics were used to summarize these vari-
ables. Statistical differences in the data were assessed
using the X2 test for categorical variables and Mann–
Whitney U-tests for continuous variables (age and time
to treatment). Since coverage was low in 2008, temporal
trend analysis was undertaken from 2009.
A logistic regression analysis was performed to assess
the impact of a number of factors (both individually and
together) on the likelihood of men not being offered any
immediate treatment (no active treatment within
12 months). In the present study, the model predicted
no active treatment (i.e. “no active treatment” outcome
was set as 1, and all other treatments as 0) from demo-
graphic characteristics (age group, residential area,
SEIFA), and diagnostic characteristics (year of diagnosis,
method of diagnosis, PSA level, Grade Group and
NCCN risk). All factors were significantly predictive and
were added to the multivariate model.
Statistical analyses were conducted using the Statistical
Package for Social Sciences (SPSS v.22). The significance
of each time trend was assessed via the Mantel-Haenszel
χ2 test for trend. Finally, we assessed the association of
sociodemographic and diagnostic variables with treatment
Table 1 Risk adjustment model adopted among men with PCa
from clinical registries in SA and Victoria
Variable NCCN
Low Clinical T1–T2a stage AND GS 2–6 AND PSA
level <10 ng/mL
Intermediate Clinical T2b–T2c stage OR GS = 7 OR PSA level
10–20 ng/mL
High Clinical T3a stage OR GS 8–10 OR PSA level
>20 ng/mL
Very high (locally
advanced)
Clinical T3b–T4
Any T, N1
Metastatic Any T, Any N, M1
NCCN National Comprehensive Cancer Network, GS Gleason Score, PSA
Prostate Specific Antigen
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selection, using the χ2or Mantel-Haenszel χ2 test, as ap-
propriate. All statistical tests were conducted at the two-
sided p < 0.05 level of significance.
Results
Demographic and diagnostic characteristics
A total of 13,598 men diagnosed with PCa between 2008
and 2013 in SA and Victoria were included in the ana-
lysis. The average (SD) age of study participants at diag-
nosis was 65.4 (9.6) years. The majority (70.5 %) of men
resided in metropolitan regions (Table 2).
The majority of men (84.7 %) were diagnosed via
transrectal ultrasound (TRUS) procedures and only
9.1 % by transurethral resection of prostate (TURP). Half
of all men (50.8 %) with recorded PSAs at the time of
diagnosis presented with PSA levels of 4.01-10 ng/mL;
one third of patients (35.1 %) were diagnosed with Grade
Group 1, followed by 27.7 % of men with Grade Group
2. The majority (42.1 %) of men were diagnosed with
intermediate risk of disease progression.
Treatment characteristics
Table 3 shows treatment types and time to the initial
treatment stratified by the NCCN risk category. Of
the men in the low NCCN risk category, nearly half
(44.2 %) had no active treatment. A large proportion
(34.7 %) of men in the same risk category had a RP,
followed by 12.5 % of men who underwent RT. The
remaining patients (0.5 %) were offered ADT or other
types of treatment (4.6 %). The median [IQR] time
between diagnosis and the active treatment in this
group was 119 [63–222.5] days.
In the intermediate NCCN risk group a significantly
higher proportion of men, relative to the low risk group,
were offered an active treatment: 54.1 % of men had a
RP, and 22.1 % of men were treated with RT. Only 9.4 %
of men had no active treatment. The median [IQR] time
between diagnosis and active treatment decreased to 80
[48–137] days.
In the high risk cancer group, 33.6 % of men had a RP
and 32.6 % were treated with RT. ADT was administered
in 15.6 % of men. A median [IQR] time between diagno-
sis and active treatment was 49 [29–96] days.
Table 2 Demographic and diagnostic characteristics among
men with PCa from clinical registries in SA and Victoria
Patients, N %
Included into the study 13,598 100
State
SA 3,526 25.9
Victoria 10,072 74.1
Age groups
< 55 2,059 15.1
56–65 4,851 35.7
65–75 4,711 34.6
> 75 1,977 14.5
Age (mean, SD) 65.4 (9.6)
Residential area
Metropolitan 9,586 70.5
Regional/Rural 3,250 23.9
Unknown 762 5.6
SEIFA
Lowest 10 % (0–20 %) 1,751 12.9
Lowest 21–40 % 2,245 16.5
Lowest 41–60 % 2,075 15.3
Highest 61–80 % 2,840 20.9
Highest 81–100 % 4,334 31.9
Unknown 353 2.6
Method of diagnosis
TRUS 11,518 84.7
TURP 1,239 9.1
Other 841 6.2
PSA (ng/mL)
< 4 2,691 19.8
4.01–10 5,985 44.0
10.01–20 1,820 13.4
> 20.01 1,284 9.4
Unknown 1,818 13.4
Grade Group
Grade Group 1 (Gleason score≤ 6) 4,769 35.1
Grade Group 2 (Gleason score 3 + 4) 3,771 27.7
Grade Group 3 (Gleason score 4 + 3) 1,832 13.5
Grade Group 4 (Gleason score 8) 1,264 9.3
Grade Group 5 (Gleason score >8) 1,193 8.8
Unknown 769 5.7
NCCN Risk
Low 3,352 24.7
Intermediate 5,727 42.1
High 2,943 21.6
Table 2 Demographic and diagnostic characteristics among
men with PCa from clinical registries in SA and Victoria
(Continued)
Very high/Metastatic 546 4.0
Unknown 1,030 7.6
SA South Australia, SEIFA Socio-Economic Index of Advantage and Disadvantage,
NCCN National Comprehensive Cancer Network, GS Gleason Score, PSA Prostate
Specific Antigen, TURP Transurethral Resection of the Prostate, TRUS Transrectal
Ultrasonography of the Prostate
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In a very high/metastasis group most of the patients
(40.1 %) were treated with ADT, followed by 28.0 % of
men who were offered RT. Only 10.4 % of patients had a
RP. A median [IQR] time to the treatment in this risk
group was significantly shorter than in other NCCN risk
groups, only 31 (12–71.5) days.
Temporal trends in demographic, diagnosis and
treatment characteristics
Annual trends of average age of men at the time of PCa
diagnosis are depicted in Fig. 1, indicating that men are
being diagnosed at slightly older age in 2013 (66.1 (SD =
9.7) years) when compared to 64.5 (SD = 9.7) years in
2009, p < 0.05.
Time trends in diagnostic characteristics are shown in
Fig. 2. About 80 % of men were diagnosed via TRUS,
and this trend remained stable from 2009–2013. A
significant increase (p < 0.05) in the proportion of men
diagnosed via “Other” diagnostic methods was noticed
in 2013 (Fig. 2a).
Figure 2b summarizes temporal trends in PSA levels at
diagnosis. Compared to 2009, fewer patients were diag-
nosed with PSA < 4.0 mL each year, while the proportion
of men with PSA 4.01–10 mL increasing from 45.8 % in
2009 to 53.5 % in 2013, p < 0.05.
Trends in Grade Group at diagnosis are shown in
Fig. 2c. The proportion of men diagnosed with Grade
Group 1 reduced from 39.9 % in 2009 to 30.9 % in 2013,
p < 0.05; while more men (31.4 %) were diagnosed with
the Grade Group 2 in 2013 when compared to 28.4 % in
2009, p < 0.05. The proportion of men with low risk
disease declined from 27.4 % in 2009 to 22.2 % in 2013,
p < 0.05 (Fig. 2d).
Trends in treatment modalities and time to the first
treatment over the five years are shown in Fig. 3. The
proportion of men with no active treatment increased
from 16.2 % in 2009 to 21.6 % in 2013, p < 0.05 (Fig. 3a).
This increase was associated with a concomitant 10 %
decline in men receiving RT (from 25.6 % to 15.6 %). RP
trend remained stable over the years.
Figure 3b depicts trends in duration (in days) between
the diagnosis and initial active treatment across NCCN
risk groups. Time interval between the diagnosis and ini-
tial treatment from 2009 to 2013 declined significantly by
62.8, 32.9, 30.3 and 39.5 days in low, intermediate, high
and v.high/metastatic NCCN risk groups respectively.
Regression analysis of factors determining surveillance of
PCa
Table 4 summarizes the contributions of each factor in
the univariate and multivariate model to men receiving
no active treatment. Univariate analysis (step 1) for all
nine categorical variables was conducted to identify fac-
tors associated with no active treatment of the disease.
The nine category variables were then added into a
multivariate model (step 2).
A full multivariate model containing all nine category
variables (inclusive of the variables with non-missing
values within each category, year of diagnosis >2008)
was statistically significant, χ2(25, N = 10,496) =7895,621,
Table 3 Treatment modalities in men with PCa from clinical registries in SA and Victoria, stratified by NCCN risk group
NCCN Risk Low* Intermediate* High* V.high/Metastasis* Total
N % N % N % N % N %
RP 1,164 34.7 3,097 54.1 988 33.6 57 10.4 5,306 42.2
RT 418 12.5 1,263 22.1 958 32.6 153 28.0 2,792 22.2
ADT 18 0.5 114 2.0 469 15.9 219 40.1 820 6.5
No active treatment 1,483 44.2 723 12.6 225 7.6 18 3.3 2,449 19.5
Other 154 4.6 307 5.4 194 6.6 45 8.2 700 5.6
Unknown 115 3.4 223 3.9 109 3.7 54 9.9 501 4.0
Total 3,352 100 5,727 100 2,943 100 546 100 12,568 100
Median [IQR] days to treatment 119 [63–222.5] 80 [48–137] 49 [29–96] 31 [12–71.5] 75 [41–142]
NCCN National Comprehensive Cancer Network, RP Radical prostatectomy, RT radiotherapy, ADT Androgen Deprivation Therapy
*p < 0.05
Fig. 1 Age trends among men diagnosed with PCa from clinical
registries in SA and Victoria
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p < 0.05) indicating ability to distinguish between men
with PCa who had no active treatment (N = 2,252) vs
other type of treatment. The model explained between
25 % (Cox and Snell R Square) and 39 % (Nagelkerke R
Square) of the variance in treatment type.
When compared to 2009, each year men were more
likely to be managed with no active treatment. For ex-
ample, men diagnosed in 2012 had nearly twice the odds
of having no active treatment (OR = 1.82, 95 % CI, 1.51–
2.21), and in 2013 even higher odds, OR = 2.63, 95 % CI,
2.16–3.22). Men older than 75 years of age had nearly
three times the odds of receiving no active treatment,
compared to younger men of 55 years or less, OR = 5.83,
(95 % CI, 4.56–7.45). Men with PCa were also more likely
not to receive an active treatment in Vic, OR = 1.49, (95 %
CI, 1.165–1.65). Men in the highest 81–100 % quintile of
SEIFA were significantly more likely to have no active
treatment (OR = 1.32, 95 % CI, 1.07–1.63), compared to
those in the lowest (0–20 %) quintile of SEIFA.
Those men whose diagnosis was detected via TURP
were more likely to not to receive an active treatment,
OR = 6.19, (95 % CI, 5.08–7.54) than men diagnosed via
TRUS. Men diagnosed with higher Grade Group were
significantly less likely to be offered an active treatment.
For example, men with Grade Group 5 had a 93 % lower
odds of receiving no active treatment than men diag-
nosed with Grade Group 1, OR = 0.07, (95 % CI, 0.05–
0.12). Similarly, men in higher NCCN risk groups were
more likely to be offered an active treatment, when com-
pared to those in a low risk category.
Discussion
General findings
To our knowledge, this was the first large-scale retro-
spective population-based cohort study for which au-
thors accessed the data records from multiple clinical
registries of men diagnosed with PCa in Australia. The
major findings of this study indicate that in the 2008–13
period: (1) men are being diagnosed at older age; (2)
diagnostic methods and characteristics have changed
and (3) types of the treatments have changed, with more
men in lower risk groups being offered no active treat-
ment, and primary radiation treatment becoming less
frequent.
Fig. 2 Trends in method of diagnosis (a), PSA levels (b), Grade Groups (c) and NCCN risk (d) among men diagnosed with PCa from clinical
registries SA and Victoria. p < 0.05 for all trends, TURP, Transurethral Resection of the Prostate; TRUS, Transrectal Ultrasonography of the Prostate
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Comparison with the existing literature
Consistent with the findings of previous studies, the
average age at diagnosis of the men in our cohort was
65 years [3, 7, 24]. However, we also observed that over
the period of five years, age at the diagnosis has slightly
increased. This could be due to the recent decline in
PSA testing among Australian men, which in turn may
be leading to men being diagnosed at an older age and
with a higher PSA [25, 26]. Consistent with this is the
decrease in proportion of men diagnosed with PSA less
than 4 ng/mL. Alternatively, younger men with low
PSAs may not have been biopsied as frequently in 2013
compared with 2008.
Nearly half of all men were diagnosed with PSA levels
of <10 mL. This became a constant trend in 2011, which
could possibly be explained by the increasing use of PSA
blood tests in case-finding from 1990–2010, resulting in
the decreased proportion of PCa patients with high PSA
levels [27]. Our findings are similar to those with Galan
et al. [28], who showed that tumours currently detected
tend to appear with lower PSA levels, and localized clin-
ical stages. A similar trend was also observed in decreas-
ing rates of high grade cancer, denoted by the Grade
Group. The proportion of men with Grade Group 1 in
2013 declined by 10 % when compared to 2009.
TRUS remains the most commonly used PCa detec-
tion method with stable trends over the years. However,
an increasing percentage of other diagnostic tools in
2013 suggest that more advanced diagnostic and investi-
gation/staging techniques such as transperineal prostate
biopsy [29] or multiparametric magnetic resonance
(mMRI), that are becoming more widely used in
Australia. mMRI is emerging as a useful tool in the in-
vestigation and treatment of PCa, by identifying regions
which may represent clinically significant PCa [30–32].
RP and RT were the most commonly offered treat-
ment types to men with PCa in SA and Victoria [10, 33].
However, recently the proportion of men undertaking
RT treatment has declined while numbers of those with
no active treatment have increased. Notably, the propor-
tion of men treated with RP did not materially change
over the years, but the higher proportion of men man-
aged with no active treatment over the time is matched
with the lower proportion of men managed with initial
RT. No active treatment is usually recommended for pa-
tients with low risk disease, older men and where active
treatment might be more harmful rather beneficial. Our
findings are similar to those of the USA and European
studies, where more men are opting for this conservative
management in [34, 35].
Fig. 3 Treatment types (a) and time to treatment (b) among men diagnosed with PCa from clinical registries in SA and Victoria. p < 0.05 for all
trends. RP – Radical Prostatectomy; RT – Radiotherapy; ADT – Androgen Deprivation Therapy
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Table 4 Factors associated with the likelihood of no active treatment in men with PCa from clinical registries in SA and Victoria
Univariate model Multivariate model
Factors Odds Ratio CI at 95 % Odds Ratio CI at 95 %
Year of Diagnosis
2009 (Ref) 1 1
2010 1.16 0.98–1.37 1.26 1.02–1.55
2011 1.32 1.13–1.53 1.43 1.18–1.73
2012 1.37 1.18–1.59 1.82 1.51–2.21
2013 1.43 1.23–1.66 2.63 2.16–3.22
Age Group
< 55 (Ref) 1 1
56–65 1.29 1.11–1.49 1.48 1.24–1.76
65–75 1.38 1.19–1.59 2.03 1.69–2.44
> 75 2.01 1.71–2.36 5.83 4.56–7.45
State
SA (Ref) 1 1
Victoria 1.74 1.54–1.95 1.49 1.16–1.65
Residential area
Metropolitan (Ref) 1 1
Regional/Rural 1.07 0.97–1.18 1.02 0.88–1.19
SEIFA
Lowest 0–20 % (Ref) 1 1
Lowest 21–40 % 0.96 0.81–1.14 0.85 0.69–1.07
Lowest 41–60 % 0.97 0.82–1.15 0.97 0.77–1.22
Highest 61–80 % 1.04 0.88–1.22 0.98 0.79–1.21
Highest 81–100 % 1.28 1.11–1.48 1.32 1.07–1.63
Method of diagnosis
TRUS (Ref) 1 1
TURP 5.23 4.61–5.93 6.19 5.08–7.54
Other 0.80 0.65–0.98 1.27 0.93–1.74
PSA (ng/mL)
< 4 (Ref) 1 1
4.01–10 0.81 0.73–0.91 1.15 0.89–1.34
10.01–20 0.62 0.53–0.72 1.65 0.92–2.07
> 20.01 0.36 0.29–0.44 1.31 0.89–1.91
Grade Group
Grade Group 1 (Gleason score ≤ 6) [Ref] 1 1
Grade Group 2 (Gleason score 3 + 4) 0.19 0.17–0.22 0.33 0.27–0.42
Grade Group 3 (Gleason score 4 + 3) 0.09 0.07–0.12 0.13 0.09–0.17
Grade Group 4 (Gleason score 8) 0.06 0.05–0.08 0.08 0.05–0.13
Grade Group 5 (Gleason score >8) 0.07 0.06–0.09 0.07 0.05–0.12
NCCN Risk
Low (Ref) 1 1
Intermediate 0.17 0.15–0.19 0.35 0.28–0.44
High 0.09 0.08–0.12 0.23 0.15–0.34
V.high/Metastatic 0.02 0.02–0.06 0.06 0.03–0.11
SA South Australia, SEIFA Socio-Economic Index of Advantage and Disadvantage, NCCN National Comprehensive Cancer Network, GS Gleason Score, PSA Prostate
Specific Antigen, TURP Transurethral Resection of the Prostate, TRUS Transrectal Ultrasonography of the Prostate
Significant rows are highlighted in bold
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We have also demonstrated that lower risk disease,
older age at diagnosis, lower PSA levels and Grade
Group were factors strongly associated with the conser-
vative management of the disease, as have others [3, 8].
Differences between the two states may be due in part
to idiosyncrasies in the way surveillance is recorded in
each registry. The trend toward increased use of no ac-
tive treatment indicates the increasing prominence of
Prostate Cancer Research International: Active Surveil-
lance guidelines which encourage clinicians to avoid ac-
tive treatment in cases where risk of progression is
considered to be low [36, 37]. Clinical registries may also
play an important role in that reporting back to clini-
cians might have impacted on the management path of
men with low risk disease [38]. Hamilton et al. [39], in a
study of seven registries in the USA, made the distinc-
tion between men receiving no therapy with no monitor-
ing plan (no therapy/no plan [NT/NP]) and those under
active surveillance or (i.e. having no active treatment)
with proposed delayed active intervention. The study
found that physician and clinical factors were stronger
predictors of active surveillance, whereas demographic
and regional factors were related to NT/NP. Older age
at diagnosis, lower clinical risk group, and geographic lo-
cation were significant predictors of use of both active
surveillance and NT/NP. Physicians appeared reluctant
to recommend no active treatment for younger patients
with no comorbidities. Loeb et al. [40] have reported
that - since 2007, 59 %, 41 % and 16 % of men in
Sweden with very low, low and intermediate risk PCa,
respectively, were under active surveillance and watchful
waiting (i.e. had no active treatment) rather had active
treatment. Age was by far the strongest determinant of
receiving no active treatment. Education, marital status
and comorbidity were significantly but weakly associated
with deferring treatment.
Study limitations and strengths
The major strength of this study is the use of clinical
registries, containing a detailed diagnosis and treatment
information of patients with PCa in SA and Victoria.
These registries enable rapid and reliable ascertainment
of patterns-of-care of patients and up-to-date reporting
back to treating clinicians [2]. However, limitations need
to be noted as well.
Firstly, treatment classification was slightly different
across states, such that we were unable to accurately de-
termine the intent of observation (i.e. whether under ac-
tive surveillance with intent to curatively treat if disease
progressed, or watchful waiting with palliative treatment
offered if necessary). Therefore these two modalities were
combined into one group called “no active treatment”.
Secondly, we were unable to assess and describe trends
in type of hospital where patients were treated as the
information in both registries was different. For example,
the type of hospital where a patient was treated in Victoria
was coded as “private” or “public” depending on the hos-
pital type; however in SA patients are classified as being
either “public” or “private” rather than that descriptor re-
lating to the health care facility [18]. Treatment type infor-
mation was missing or unknown in ~14 % of cases. We
were unable to assess the impact of comorbidities such as
chronic illness and obesity on patterns of disease manage-
ment as such information is not collected in either regis-
try. In addition, neither state had 100 % population
coverage of PCa cases.
Conclusions
This was the first study to describe patterns of care and
trends in diagnostic characteristics in men with PCa
across two registries in Australia. The recently developed
PCOR-ANZ will collect patterns of care and standardised
patient reported QOL measures of men nation-wide in
Australia and New Zealand [17]. This information will be
incorporated into future analyses to be conducted and will
assist in transforming healthcare for men with PCa in
Australia and New Zealand by encouraging change in
practice in line with guidelines/recommendations (e.g. of-
fering active surveillance in low risk disease and observa-
tion for older men with less life expectancy) through
monitoring and reporting outcomes and feedback to clini-
cians caring for men with PCa.
Abbreviations
ADT, Androgen Deprivation Therapy; IQR, interquartile range; mMRI,
multiparametric magnetic resonance imaging; NCCN, National Comprehensive
Cancer Network; NT/NP, no therapy/no plan; OR, odds ratio; PCa, prostate
cancer; PCOR-ANZ, Australian and New Zealand Prostate Cancer Outcomes
Registry; PCOR-Vic, Prostate Cancer Outcomes Registry – Victoria; PSA, prostate-
specific antigen; QOL, quality of life; RP, radical prostatectomy; RT, radiation
therapy; SA, South Australia; SAHMRI, South Australian Health and Medical
Research Institute; SA-PCCOC, South Australian Prostate Cancer Clinical
Outcomes Collaborative; SD, standard deviation; SEIFA, socio-economic index of
advantage and disadvantage; TRUS, transrectal ultrasonography of the prostate;
TURP, transurethral resection of the prostate; Vic, Victoria
Acknowledgements
We would like to thank Ms Fanny Sampurno (data manager of PCOR-Vic), Mr
Scott Walsh (data manager of SA-PCCOC) and Ms Tina Kopsaftis (clinical data
coordinator at SA-PCCOC) for their support and contribution.
Funding
This study was supported by Movember Foundation. SE received a Monash
Partners Academic Fellowship.
Availability of data and materials
Data from individual registries is available under individual data access policy in
each state. Access to the data is guided by strict protocols and procedures to
ensure that the privacy of men and other ethical principles are maintained at all
times. The data access policy and data request form for the PCOR-Vic is
available to access by registering through the website address at http://pcr.re-
gistry.org.au/Home.aspx. Information about the SA-PCCOC data can be found
at http://www.sa-pccoc.com. Requests to access data from the SA-PCCOC
registry should be addressed to the research committee for review and
consideration (contactus@sa-pccoc.com). Requests for data to support
commercial activities are not considered.
Ruseckaite et al. BMC Cancer  (2016) 16:607 Page 9 of 11
Authors’ contributions
RR designed the study, conducted data analysis and wrote the manuscript.
MO’C and KB participated in its design, helped with the preparation of the
dataset and coordination and helped to draft the manuscript. JM and DR
provided conceptual advice. DR, KM and SE conceived the study, and KM
and SE were the principal investigators. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval for this study was gained from Monash University and
University of SA.
Author details
1Department of Epidemiology and Preventive Medicine, Monash University,
Melbourne, VIC, Australia. 2Centre for Population Health Research, Sansom
Institute for Health Research, University of South Australia, Adelaide, SA,
Australia. 3South Australian Prostate Cancer Clinical Outcomes Collaborative,
Department of Urology, Repatriation General Hospital, Adelaide, SA, Australia.
4Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, SA,
Australia. 5Freemasons Foundation Centre for Men’s Health and Discipline of
Medicine, University of Adelaide, Adelaide, SA, Australia. 6Radiation Oncology,
Alfred Health, Melbourne, VIC, Australia.
Received: 14 December 2015 Accepted: 30 July 2016
References
1. Center M, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F.
International variation in prostate cancer incidence and mortality rates. Eur
Urol 2012, 61(6):doi: 10.1016/j.eururo.2012.1002.1054. Epub 2012 Mar 1018.
2. Evans S, Millar J, Wood J, Davis I, Bolton D, Giles G, Frydenberg M, Frauman
A, Costello A, McNeil J. The prostate cancer registry: monitoring paterns and
quality of care for men diagnosed with prostate cancer. BJU Int. 2012;111:
e158–66.
3. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM,
Carroll PR. The contemporary management of prostate cancer in the United
States: Lessons from the cancer of the prostate strategic urologic research
endeavor (capsure), a national disease registry. J Urol. 2004;171(4):1393–401.
4. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K,
Murphy DG, Penson DF, Miller DC. Prostate cancer registries: Current status
and future directions. Eur Urol. 2016;69(6):998–1012. doi:10.1016/j.eururo.
2015.05.046. Epub 2015 Jun 6.
5. South Australian Prostate Cancer Clinical Outcome Collaborative [http://
www.sa-pccoc.com]; 1998.
6. Schmidt S, Garin O, Pardo Y, Valderas J, Alonso J, Rebollo P, Rajmil L, Garcia-
Forero C, Ferrer F. Assessing quality of life in patients with prostate cancer:
A systematic and standardized comparison of available instruments. Qual
Life Res 2014. doi:10.1007/s11136-014-0678-8.
7. Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP. An
examination of prostate cancer trends in Australia, England, Canada and
USA: Is the australian death rate too high? World J Urol. 2015;33(11):1677–
87. doi:10.1007/s00345-015-1514-7. Epub 2015 Feb 20
8. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of
treatment after initial surveillance in men with prostate cancer: results from
capsure. J Urol. 2003;170(6 Pt 1):2279–83.
9. Beckmann K, Pinnock C, Tamblyn D, Kopsaftis T, AMF S, Roder D. Clinical
and socio-demographic profile of an australian multi-institutional prostate
cancer cohort. Clin Oncol. 2009;5:247–56.
10. Evans S, Millar J, Davis C, Murphy D, Bolton D, Giles G, Frydenberg M,
Andrianopoulos N, Wopod J, Frauman A, et al. Patterns of care for men
diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust.
2013;198(10):540–5.
11. Evans S, Millar J, Frydenberg M, Murphy D, Davis C, Spelman T, Bolton D,
Giles G, Dean J, Costello A et al. Positive surgical margins: Rate, contributing
factors and impact on further treatment: Findings from the prostate cancer
registry. BJU Int 2013, doi: 10.1111/bju.12509
12. Smith D, King M, Egger S, Berry M, Stricker P, P C, Ward J, DL OC, Armstrong
B. Quality of life three years after diagnosis of localised prostate cancer:
Population based cohort study. BMJ. 2009;339:b4817. doi:10.1136/bmj.
b4817.
13. Baade PD, Youlden DR, Coory MD, Gardiner RA, Chambers SK. Urban–rural
differences in prostate cancer outcomes in Australia: what has changed?
Med J Aust. 2011;194(6):293–6.
14. Adami H, Bergstrom R, Mohner M, Zatosnki W, Storm H, Ekbom A, Tretli S,
Teppo L, Ziegler H, Rahu M, et al. Testicular cancer in nine northern
european countries. Int J Cancer. 1994;59:33–8.
15. Coleman M, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U,
Tracey E, Coory M, Hatcher J, et al. Cancer survival in Australia, Canada,
Denmark, Norway, Sweden, and the UK, 1995–2007 (the international
cancer benchmarking partnership): an analysis of population-based cancer
registry data. Lancet. 2011;377:127–38.
16. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler
I. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-
4 data. Lancet. 2007;8:784–96.
17. Evans S, Nag N, Roder D, Brooks A, Millar J, Moretti K, Pryor D, Skala M,
McNeil J. Development of the international Prostate Cancer Outcomes
Registry. BJU Int 2015, doi: 10.1111/bju.13258
18. Ruseckaite R, Beckmann K, O’Callaghan M, Roder D, Moretti K, Zalcberg J,
Millar J, Evans S. Development of South Australian-Victorian Prostate Cancer
Health Outcomes Research Dataset (SA-VIC PCHORD). BMC Res Notes. 2016;
9:37. doi:10.1186/s13104-016-1855-3.
19. Victorian Prostate Cancer Clinical Registry (PCR). 2008. http://pcr.registry.org.au.
Accessed Nov 2015.
20. Australian Bureau of Statistics. 2015. www.abs.gov.au. Accessed Nov 2015.
21. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers
AJ, Parwani AV, Reuter VE, Fine SW et al. A contemporary prostate cancer grading
system: A validated alternative to the gleason score. Eur Urol. 2016;69(3):428–35.
doi:10.1016/j.eururo.2015.06.046. Epub 2015 Jul 10.
22. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The
2014 international society of urological pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma: definition of
grading patterns and proposal for a new grading system. Am J Surg Pathol.
2016;40(2):244–52.
23. Prostate cancer staging. Https://cancerstaging.Org/references-tools/
quickreferences/documents/prostatesmall.Pdf 2015.
24. Boscoe FP, Pradhan E. A medicare-associated spike in U.S. Cancer rates at
age 65, 2000–2010. Public Health Rep. 2015;130(4):343–8.
25. O’Kelly F, Thomas A, Murray D, Galvin D, Mulvin D, Quinlan DM. Can
delayed time to referral to a tertiary level urologist with an abnormal PSA
level affect subsequent gleason grade in the opportunistically screened
population? Prostate. 2013;73(12):1263–9.
26. Roumiguie M, Beauval JB, Bordier B, Filleron T, Rozet F, Ruffion A, Mottet N,
Cussenot O, Malavaud B. What risk of prostate cancer led urologist to
recommend prostate biopsies? Prog Urol. 2015;25(16):1125–31. doi:10.1016/j.
purol.2015.08.007. Epub 2015 Oct 1.
27. Kitagawa Y, Machioka K, Yaegashi H, Nakashima K, Ofude M, Izumi K, Ueno
S, Kadono Y, Konaka H, Mizokami A, et al. Decreasing trend in prostate
cancer with high serum prostate-specific antigen levels detected at first
prostate-specific antigen-based population screening in Japan. Asian J
Androl. 2014;16(6):833–7.
28. Lujan Galan M, Paez Borda A, Chiva Robles V, Santonja Garriga C, Romero
Cajigal I, Berenguer Sanchez A. Epidemiological trends in prostate cancer
over the last years. Arch Esp Urol. 2004;57(8):817–25.
29. Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K.
Transperineal prostate biopsy detects significant cancer in patients with
elevated prostate-specific antigen (PSA) levels and previous negative
transrectal biopsies. BJU Int. 2012;110(2 Pt 2):E69–75.
30. Pedler K, Kitzing YX, Varol C, Arianayagam M. The current status of MRI in
prostate cancer. Aust Fam Physician. 2015;44(4):225–30.
31. Scheenen TW, Rosenkrantz AB, Haider MA, Futterer JJ. Multiparametric
magnetic resonance imaging in prostate cancer management: Current
status and future perspectives. Invest Radiol. 2015;50(9):594–600.
32. Katelaris NC, Bolton DM, Weerakoon M, Toner L, Katelaris PM, Lawrentschuk
N. Current role of multiparametric magnetic resonance imaging in the
management of prostate cancer. Korean J Urol. 2015;56(5):337–45.
Ruseckaite et al. BMC Cancer  (2016) 16:607 Page 10 of 11
33. Frydenberg M. Prostate cancer: care beyond prostate cancer-improving
patient outcomes. Nat Rev Urol. 2014;11(12):669–71.
34. McCarthy M. More US men with low risk prostate cancer opt for watchful
waiting. BMJ. 2015;351:h3777.
35. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, Stabenow R,
Froehner M, Huber J. Integrated prostate cancer centers might cause an
overutilization of radiotherapy for low-risk prostate cancer: a comparison of
treatment trends in the united states and Germany from 2004 to 2011.
Radiother Oncol. 2015;115(1):90–5.
36. Bangma CH, Bul M, Roobol M. The prostate cancer research international:
active surveillance study. Curr Opin Urol. 2012;22(3):216–21.
37. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der
Schoot DK, Cornel EB, Conti GN, et al. Active surveillance for low-risk
prostate cancer worldwide: The PRIAS study. Eur Urol. 2013;63(4):597–603.
38. Weerakoon M, Papa N, Lawrentschuk N, Evans S, Millar J, Frydenberg M,
Bolton D, Murphy DG. The current use of active surveillance in an Australian
cohort of men: a pattern of care analysis from the Victorian prostate cancer
registry. BJU Int. 2015;115 Suppl 5:50–6.
39. Hamilton AS, Wu XC, Lipscomb J, Fleming ST, Lo M, Wang D, Goodman M,
Ho A, Owen JB, Rao C, et al. Regional, provider, and economic factors
associated with the choice of active surveillance in the treatment of men
with localized prostate cancer. J Natl Cancer Inst Monogr. 2012;2012(45):
213–20.
40. Loeb S, Berglund A, Stattin P. Population based study of use and
determinants of active surveillance and watchful waiting for low and
intermediate risk prostate cancer. J Urol. 2013;190(5):1742–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ruseckaite et al. BMC Cancer  (2016) 16:607 Page 11 of 11
